WO2021163280A3 - Wp1 tau aggregation inhibitor peptide from woodpecker homolog - Google Patents

Wp1 tau aggregation inhibitor peptide from woodpecker homolog Download PDF

Info

Publication number
WO2021163280A3
WO2021163280A3 PCT/US2021/017594 US2021017594W WO2021163280A3 WO 2021163280 A3 WO2021163280 A3 WO 2021163280A3 US 2021017594 W US2021017594 W US 2021017594W WO 2021163280 A3 WO2021163280 A3 WO 2021163280A3
Authority
WO
WIPO (PCT)
Prior art keywords
tau
woodpecker
aggregation
tau protein
homolog
Prior art date
Application number
PCT/US2021/017594
Other languages
French (fr)
Other versions
WO2021163280A2 (en
Inventor
David S. Eisenberg
Paul M. SEIDLER
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Publication of WO2021163280A2 publication Critical patent/WO2021163280A2/en
Publication of WO2021163280A3 publication Critical patent/WO2021163280A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/465—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from birds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Aggregation of Tau protein into amyloid fibrils has been linked to cognitive decline in over 20 dementias including Alzheimer's Disease (AD) and Chronic Traumatic Encephalopathy (CTE), a neurodegenerative disorder associated with repetitive head trauma that is enriched in certain populations including athletes who participate in high impact sports, and soldiers. Here we show that Tau protein from downy woodpecker is less prone than human Tau both to aggregation and to the seeded spread of Tau fibrils which accounts for progression of tauopathies. Embodiments of the invention include Tau aggregation inhibitory peptides having amino acid sequences found in downy woodpecker Tau protein and methods for making and using these peptides.
PCT/US2021/017594 2020-02-11 2021-02-11 Wp1 tau aggregation inhibitor peptide from woodpecker homolog WO2021163280A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062972885P 2020-02-11 2020-02-11
US62/972,885 2020-02-11

Publications (2)

Publication Number Publication Date
WO2021163280A2 WO2021163280A2 (en) 2021-08-19
WO2021163280A3 true WO2021163280A3 (en) 2021-10-14

Family

ID=77295181

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/017594 WO2021163280A2 (en) 2020-02-11 2021-02-11 Wp1 tau aggregation inhibitor peptide from woodpecker homolog

Country Status (1)

Country Link
WO (1) WO2021163280A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116716352A (en) * 2023-05-16 2023-09-08 深圳湾实验室 Cell model for Tau protein aggregation, construction method and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200017563A1 (en) * 2017-03-15 2020-01-16 The Regents Of The University Of California Structure-based peptide inhibitors that target the tau vqiink fibrillization segment

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200017563A1 (en) * 2017-03-15 2020-01-16 The Regents Of The University Of California Structure-based peptide inhibitors that target the tau vqiink fibrillization segment

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE UniProt [online] 11 December 2019 (2019-12-11), Database accession no. A0A093G1 H2 *
FARAH ET AL.: "Tau accumulations in the brains of woodpeckers", PLOS ONE, vol. 13, no. 2, 2 February 2018 (2018-02-02), pages e0191526, XP055866318 *

Also Published As

Publication number Publication date
WO2021163280A2 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
EP4299118A3 (en) Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
WO2021163280A3 (en) Wp1 tau aggregation inhibitor peptide from woodpecker homolog
RU2008126294A (en) METHODS FOR TREATING MUSCULAR LOSS
JP2006506942A5 (en)
JP2020530843A5 (en)
HRP20220860T1 (en) Cxcr4 binding molecules
RU2011100127A (en) COMPOUND CONTAINING A PEPTIDE FOR TREATING SYMPTOMS OF PARKINSON'S DISEASE
HRP20160392T1 (en) Pcsk9 vaccine
Yu et al. Serum amyloid a differentially activates microglia and astrocytes via the PI3K pathway
US9682140B2 (en) Ezrin-derived peptides and pharmaceutical compositions thereof
RU2016135003A (en) NEW TYPES OF TREATMENT
JP2017519763A5 (en)
RU2014103246A (en) COMPOUNDS AND PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE AND ISCHEMIC BRAIN DISEASES
EA202190334A1 (en) PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION WITH MODIFIED RELEASE
RU2010128602A (en) CYCLIC PROTEIN NOT CONTAINING CRYSTEIN RESIDUES
Engelsen et al. Increased concentrations of aspartic acid in the cerebrospinal fluid of patients with epilepsy and trigeminal neuralgia: an effect of medication?
JP2018529625A5 (en)
JP2019534247A5 (en)
EP3134428B1 (en) Polypeptide fragments of 168a-t2 and compositions comprising them for use in treating cancer
ATE552271T1 (en) ANTITUMOR MEDICINE, DRUG, COMPOSITION AND USE THEREOF
RU2018125290A (en) Pharmaceutical compositions and their use for the treatment of retinitis pigmentosa
Wirawan et al. Neurological manifestations in COVID-19 infection
Pekel’dina et al. ANGIOTROPIC EFFECTS OF DIPEPTIDE MIMETICS OF NERVE GROWTH FACTOR
US11498943B2 (en) Amyloid inhibitory peptides
JP2018027911A (en) Antipruritic agent

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21753593

Country of ref document: EP

Kind code of ref document: A2